Strategies for drug delivery to the central nervous system by systemic route

References

• Abbott NJ, Revest PA. (1991). Control of brain endothelial permeability. Cerebrovasc Brain Metab Rev 3:39–72
   PubMedGoogle Scholar
• Abbott NJ, Ronnback L, Hansson E. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53
   PubMed Web of Science ®Google Scholar
• Agarwal S, Sane R, Ohlfest JR, Elmquist WF. (2011). The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223–33
   PubMed Web of Science ®Google Scholar
• Ahmed-belkacem A, Pozza A, Muñoz-martínez F, et al. (2005). Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Canc Res 65:4852–60
   PubMed Web of Science ®Google Scholar
• Akhtar N, Ahad A, Khar RK, et al. (2011). The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 21:561–76
   PubMed Web of Science ®Google Scholar
• Albanese A, Tang PS, Chan WCW. (2012). The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16
   PubMed Web of Science ®Google Scholar
• Amin ML. (2013). p-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34
   PubMedGoogle Scholar
• Andrieux K, Garcia-Garcia E, Kim HR, Couvreur P. (2009). Colloidal carriers: a promising way to treat central nervous system diseases. J Nanoneurosci 1:17–34
   Google Scholar
• Aoki H, Kakinuma K, Morita K, et al. (2004). Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hyperthermia 20:595–605
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter JA, Redeker S, et al. (2005). Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849–57
   PubMed Web of Science ®Google Scholar
• Batchelder EM, Yarar D. (2010). Differential requirements for clathrin-dependent endocytosis at sites of cell-substrate adhesion. Mol Biol Cell 21:3070–9
   PubMed Web of Science ®Google Scholar
• Begley DJ. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48:136–46
   PubMed Web of Science ®Google Scholar
• Begley DJ. (2004a). ABC transporters and the blood-brain barrier. Curr Pharm Des 10:1295–312
   PubMed Web of Science ®Google Scholar
• Begley DJ. (2004b). Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29–45
   PubMed Web of Science ®Google Scholar
• Begley DJ, Brightman MW. (2003). Structural and functional aspects of the blood-brain barrier. Prog Drug Res 61:39–78
   PubMedGoogle Scholar
• Bergmann P, Kacenelenbogen R, Vizet A. (1984). Plasma clearance, tissue distribution and catabolism of cationized albumins with increasing isoelectric points in the rat. Clin Sci (Lond) 67:35–43
   PubMed Web of Science ®Google Scholar
• Bickel U, Yoshikawa T, Pardridge WM. (1993). Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 10:205–45
   Web of Science ®Google Scholar
• Bickel U, Yoshikawa T, Pardridge WM. (2001). Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 46:247–79
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–302
   PubMed Web of Science ®Google Scholar
• Brigger I, Morizet J, Laudani L, et al. (2004). Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release 100:29–40
   PubMed Web of Science ®Google Scholar
• Brightman MW, Hori M, Rapoport SI, et al. (1973). Osmotic opening of tight junctions in cerebral endothelium. J Comp Neurol 152:317–25
   PubMed Web of Science ®Google Scholar
• Burg D, Wielinga P, Zelcer N, et al. (2002). Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol 62:1160–6
   PubMed Web of Science ®Google Scholar
• Burgess A, Hynynen K. (2013). Noninvasive and targeted drug delivery to the brain using focused ultrasound. ACS Chem Neurosci 4:519–26
   PubMed Web of Science ®Google Scholar
• Butt AM, Jones HC, Abbott NJ. (1990). Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 429:47–62
   PubMed Web of Science ®Google Scholar
• Calvo P, Gouritin B, Chacun H, et al. (2001). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18:1157–66
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chin JE, Ueda K, et al. (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381–9
   PubMed Web of Science ®Google Scholar
• Cooray HC, Blackmore CG, Maskell L, Barrand MA. (2002). Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059–63
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505–22
   PubMed Web of Science ®Google Scholar
• Davson H. (1978). The environment of the neurone. Trends Neurosci 1:39–41
   Google Scholar
• Deeken JF, Loscher W. (2007). The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663–74
   PubMed Web of Science ®Google Scholar
• Di Polo A, Aigner LJ, Dunn RJ, et al. (1998). Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci USA 95:3978–83
   PubMed Web of Science ®Google Scholar
• Dietz GP, Bahr M. (2004). Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 27:85–131
   PubMed Web of Science ®Google Scholar
• Dietz GP, Kilic E, Bahr M. (2002). Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci 21:29–37
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–70
   PubMed Web of Science ®Google Scholar
• Drummond DC, Zignani M, Leroux J-C. (2000). Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39:409–60
   PubMed Web of Science ®Google Scholar
• ECK SL. (1999). The prospects for gene therapy. Hosp Pract (Minneap) 34:67–75
   Web of Science ®Google Scholar
• Finlay JL, Goldman S, Wong MC, et al. (1996). Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol 14:2495–503
   PubMed Web of Science ®Google Scholar
• Garcia-garcia E, Andrieux K, Gil S, Couvreur P. (2005). Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298:274–92
   PubMed Web of Science ®Google Scholar
• Gellman SH. (1998). Foldamers: a manifesto. Acc Chem Res 31:173–80
   Web of Science ®Google Scholar
• Gold BG. (2000). Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs 9:2331–42
   PubMed Web of Science ®Google Scholar
• Golden PL, Pollack GM. (2003). Blood-brain barrier efflux transport. J Pharm Sci 92:1739–53
   PubMed Web of Science ®Google Scholar
• Grazia Cascone M, Zhu Z, Borselli F, Lazzeri L. (2002). Poly(vinyl alcohol) hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles. J Mater Sci Mater Med 13:29–32
   PubMed Web of Science ®Google Scholar
• Greenwald RB, Pendri A, Bolikal D. (1995). Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. J Org Chem 60:331–6
   Web of Science ®Google Scholar
• Hamilton GS. (1998). Immunophilin ligands for the treatment of neurological disorders. Expert Opin Ther Pat 8:1109–24
   Web of Science ®Google Scholar
• Hansen CG, Nichols BJ. (2009). Molecular mechanisms of clathrin-independent endocytosis. J Cell Sci 122:1713–21
   PubMed Web of Science ®Google Scholar
• Hariton-Gazal E, Feder R, Mor A, et al. (2002). Targeting of nonkaryophilic cell-permeable peptides into the nuclei of intact cells by covalently attached nuclear localization signals. Biochemistry 41:9208–14
   PubMed Web of Science ®Google Scholar
• Hart M, Beeson C. (2001). Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation. J Med Chem 44:3700–9
   PubMed Web of Science ®Google Scholar
• Hervé F, Ghinea N, Scherrmann J-M. (2008). CNS delivery via adsorptive transcytosis. AAPS J 10:455–72
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. (2009). Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66:2873–96
   PubMed Web of Science ®Google Scholar
• Hirase T, Staddon JM, Saitou M, et al. (1997). Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 110:1603–13
   PubMed Web of Science ®Google Scholar
• Hu K, Li J, Shen Y, et al. (2009). Lactoferrin-conjugated PEGPLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Rel 134:55–61
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164–9
   PubMed Web of Science ®Google Scholar
• Hynynen K. (2007). Focused ultrasound for blood-brain disruption and delivery of therapeutic molecules into the brain. Expert Opin Drug Deliv 4:27–35
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
   PubMed Web of Science ®Google Scholar
• Inamura T, Black KL. (1994). Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14:862–70
   PubMed Web of Science ®Google Scholar
• Jain KK. (2007). Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis 4:287–91
   PubMed Web of Science ®Google Scholar
• Jamshidian M, Tehrany EA, Imran M, et al. (2010). Poly-lactic acid: production, applications, nanocomposites, and release studies. Comp Rev Food Sci Food Saf 9:552–71
   PubMed Web of Science ®Google Scholar
• Jordão JF, Ayala-Grosso CA, Markham K, et al. (2010). Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-β plaque load in the TgCRND8 mouse model of Alzheimer’s disease. PloS One 5:e10549
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L. (2008). The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099–106
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L, Schmitt F. (2007). Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med Res Rev 27:574–90
   PubMed Web of Science ®Google Scholar
• Kakinuma K, Tanaka R, Takahashi H, et al. (1996). Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int J Hyperthermia 12:157–65
   PubMed Web of Science ®Google Scholar
• Karanth H, Murthy RSR. (2007). pH-sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol 59:469–83
   PubMed Web of Science ®Google Scholar
• Karnovsky MJ. (1967). The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J Cell Biol 35:213–36
   PubMed Web of Science ®Google Scholar
• Kong G, Dewhirst MW. (1999). Review hyperthermia and liposomes. Int J Hyperthermia 15:345–70
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J, et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767–73
   PubMed Web of Science ®Google Scholar
• Kreuter J, Gelperina S. (2008). Use of nanoparticles for cerebral cancer. Tumori 94:271–7
   PubMed Web of Science ®Google Scholar
• Kreuter J, Swarbrick J, Boylan JC. (1994). Encyclopedia of pharmaceutical technology. Florida: CRC Press
   Google Scholar
• Kroll RA, Neuwelt EA. (1998). Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42:1083–99; discussion 1099–100
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–18
   PubMed Web of Science ®Google Scholar
• Lam FC, Liu R, Lu P, et al. (2001). β-Amyloid efflux mediated by p-glycoprotein. J Neurochemistry 76:1121–8
   PubMed Web of Science ®Google Scholar
• Letvin NL, Goldmacher VS, Ritz J, et al. (1986). In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest 77:977–84
   PubMed Web of Science ®Google Scholar
• Li J, Zhang C, Li J, et al. (2013). Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides. Pharm Res 30:1813–23
   PubMed Web of Science ®Google Scholar
• Li Z, Li Q, Simon S, et al. (2007). Formulation of spray-dried phenytoin loaded poly (ɛ-caprolactone) microcarrier intended for brain delivery to treat epilepsy. J Pharm Sci 96:1018–30
   PubMed Web of Science ®Google Scholar
• Liu L, Guo K, Lu J, et al. (2008a). Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 29:1509–17
   PubMed Web of Science ®Google Scholar
• Liu L, Venkatraman SS, Yang YY, et al. (2008b). Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers 90:617–23
   PubMed Web of Science ®Google Scholar
• Liu S, Levine SR, Winn HR. (2010). Targeting ischemic penumbra: part I-from pathophysiology to therapeutic strategy. J Exp Stroke Transl Med 3:47–55
   PubMedGoogle Scholar
• Lockman PR, Koziara JM, Mumper RJ, Allen DD. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 12:635–41
   PubMed Web of Science ®Google Scholar
• Maldonado-Báez L, Williamson C, Donaldson JG. (2013). Clathrin-independent endocytosis: a cargo-centric view. Exp Cell Res 319:2759–69
   PubMed Web of Science ®Google Scholar
• Mayor S, Pagano RE. (2007). Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8:603–12
   PubMed Web of Science ®Google Scholar
• Michaelis K, Hoffmann MM, Dreis S, et al. (2006). Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317:1246–53
   PubMed Web of Science ®Google Scholar
• Minich T, Riemer J, Schulz JRB, et al. (2006). The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J Neurochemistry 97:373–84
   PubMed Web of Science ®Google Scholar
• Misra A, Ganesh S, Shahiwala A, Shah SP. (2003). Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6:252–73
   PubMed Web of Science ®Google Scholar
• Missirlis D, Tirelli N, Hubbell JA. (2005). Amphiphilic hydrogel nanoparticles. Preparation, characterization, and preliminary assessment as new colloidal drug carriers. Langmuir 21:2605–13
   PubMed Web of Science ®Google Scholar
• Mousavi S, Malerd L, Berg T, Kjeken R. (2004). Clathrin-dependent endocytosis. Biochem J 377:1–16
   PubMed Web of Science ®Google Scholar
• Mu C, Dave N, Hu J, et al. (2013). Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J Microencapsul 30:701–8
   PubMed Web of Science ®Google Scholar
• Mufamadi MS, Pillay V, Choonara YE, et al. (2011). A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv 2011:1–19
   Google Scholar
• Musumeci T, Ventura CA, Giannone I, et al. (2006). PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 325:172–9
   PubMed Web of Science ®Google Scholar
• Nakano S, Matsukado K, Black KL. (1996). Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 56:4027–31
   PubMed Web of Science ®Google Scholar
• Natta FJV, Hill JW, Carothers WH. (1934). Studies of polymerization and ring formation. XXIII. 1 ɛ-caprolactone and its polymers. J Am Chem Soc 56:455–7
   Google Scholar
• Needham D, Dewhirst MW. (2001). The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 53:285–305
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Katneni K. (2009). Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem 9:130–47
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (1991). Peptide drug delivery to the brain. New York: Raven Press
   Google Scholar
• Pardridge WM. (1998). CNS drug design based on principles of blood-brain barrier transport. J Neurochem 70:1781–92
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2002). Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131–9
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2003). Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3:90–105, 51
   PubMedGoogle Scholar
• Pardridge WM, Boado RJ, Buciak JL. (1993). Drug delivery of antisense oligonucleotides or peptides to tissues in vivo using an avidin-biotin system. Drug Deliv 1:43–50
   Google Scholar
• Pardridge WM, Triguero D, Buciak JL. (1990a). Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. Endocrinology 126:977–84
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Triguero D, Yang J, Cancilla PA. (1990b). Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 253:884–91
   PubMed Web of Science ®Google Scholar
• Patch JA, Barron AE. (2002). Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers. Curr Opin Chem Biol 6:872–7
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. (2006). Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223–36
   PubMed Web of Science ®Google Scholar
• Poduslo JF, Curran GL, Gill JS. (1998). Putrescine-modified nerve growth factor: bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J Neurochemistry 71:1651–60
   PubMed Web of Science ®Google Scholar
• Rapoport M, Lorberboum-Galski H. (2009). TAT-based drug delivery system–new directions in protein delivery for new hopes? Expert Opin Drug Deliv 6:453–63
   PubMed Web of Science ®Google Scholar
• Rapoport SI. (1970). Effect of concentrated solutions on blood-brain barrier. Am J Physiol 219:270–4
   PubMed Web of Science ®Google Scholar
• Reese TS, Karnovsky MJ. (1967). Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207–17
   PubMed Web of Science ®Google Scholar
• Ren J, Shen S, Wang D, et al. (2012). The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33:3324–33
   PubMed Web of Science ®Google Scholar
• Rusnati M, Coltrini D, Oreste P, et al. (1997). Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem 272:11313–20
   PubMed Web of Science ®Google Scholar
• Sadeque AJM, Wandel C, He H, et al. (2000). Increased drug delivery to the brain by P-glycoprotein inhibition&ast. Clin Pharmacol Ther 68:231–7
   PubMed Web of Science ®Google Scholar
• Saiyed ZM, Gandhi NH, Nair MPN. (2010). Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine 5:157–66
   PubMed Web of Science ®Google Scholar
• Sanovich E, Bartus RT, Friden PM, et al. (1995). Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 705:125–35
   PubMed Web of Science ®Google Scholar
• Schnyder A, Huwyler JR. (2005). Drug transport to brain with targeted liposomes. NeuroRx 2:99–107
   PubMedGoogle Scholar
• Schoenmakers RG, Van de Wetering P, Elbert DL, Hubbell JA. (2004). The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release 95:291–300
   PubMed Web of Science ®Google Scholar
• Seelig A. (1998). A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252–61
   PubMedGoogle Scholar
• Selmaj K. (1996). Pathophysiology of the blood-brain barrier. Germany: Springer
   Google Scholar
• Shamenkov DA, Petrov VE, Alyautdin RN. (2006). Effects of apolipoproteins on dalargin transport across the blood-brain barrier. Bull Exp Biol Med 142:703–6
   PubMed Web of Science ®Google Scholar
• Sinha VR, Bansal K, Kaushik R, et al. (2004). Poly-ɛ-caprolactone microspheres and nanospheres: an overview. Int J Pharm 278:1–23
   PubMed Web of Science ®Google Scholar
• Snyder SH, Sabatini DM. (1995). Immunophilins and the nervous system. Nat Med 1:32–7
   PubMed Web of Science ®Google Scholar
• Song BW, Vinters HV, Wu D, Pardridge WM. (2002). Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther 301:605–10
   PubMed Web of Science ®Google Scholar
• Soni V, Kohli DV, Jain SK. (2005). Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target 13:245–50
   PubMed Web of Science ®Google Scholar
• Strausbaugh LJ, Brinker GS. (1983). Effect of osmotic blood-brain barrier disruption on gentamicin penetration into the cerebrospinal fluid and brains of normal rabbits. Antimicrob Agents Chemother 24:147–50
   PubMed Web of Science ®Google Scholar
• Takeshima K, Chikushi A, Lee KK, et al. (2003). Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes. J Biol Chem 278:1310–15
   PubMed Web of Science ®Google Scholar
• Tenzer S, Docter D, Kuharev JR, et al. (2013). Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 8:772–81
   PubMed Web of Science ®Google Scholar
• Tenzer S, Docter D, Rosfa S, et al. (2011). Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5:7155–67
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Amiji MM. (2006). A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3:219–32
   PubMedGoogle Scholar
• Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–60
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2008). Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90:604–10
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Shtilman MI, Trubetskoy VS, et al. (1994). Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochimica et Biophysica Acta (BBA)-Biomembranes 1195:181–4
   PubMed Web of Science ®Google Scholar
• Tran TA, Mattern RH, Afargan M, et al. (1998). Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues. J Med Chem 41:2679–85
   PubMed Web of Science ®Google Scholar
• Treat LH, Mcdannold N, Vykhodtseva N, et al. (2007). Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121:901–7
   PubMed Web of Science ®Google Scholar
• Triguero D, Buciak J, Pardridge WM. (1990). Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochemistry 54:1882–8
   PubMed Web of Science ®Google Scholar
• Triguero D, Buciak JB, Yang J, Pardridge WM. (1989). Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA 86:4761–5
   PubMed Web of Science ®Google Scholar
• Triguero D, Buciak JL, Pardridge WM. (1991a). Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J Pharmacol Exp Ther 258:186–92
   PubMed Web of Science ®Google Scholar
• Triguero D, Buciak JL, Pardridge WM. (1991b). Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J Pharmacol Exp Ther 258:186–92
   PubMed Web of Science ®Google Scholar
• Tyagi M, Rusnati M, Presta M, Giacca M. (2001). Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:3254–61
   PubMed Web of Science ®Google Scholar
• Van Rooy I, Cakir-Tascioglu S, Couraud P-O, et al. (2010). Identification of peptide ligands for targeting to the blood-brain barrier. Pharmaceut Res 27:673–82
   PubMed Web of Science ®Google Scholar
• Van Rooy I, Hennink WE, Storm G, et al. (2012). Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding. Eur J Pharm Sci 45:330–5
   PubMed Web of Science ®Google Scholar
• Werle M. (2008). Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 25:500–11
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Gelperina S, Kreuter J. (2012). Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161:264–73
   PubMed Web of Science ®Google Scholar
• Wolburg H, Lippoldt A. (2002). Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323–37
   PubMed Web of Science ®Google Scholar
• Woodruff MA, Hutmacher DW. (2010). The return of a forgotten polymer-polycaprolactone in the 21st century. Progr Polymer Sci 35:1217–56
   Web of Science ®Google Scholar
• Xiao G, Gan L-S. (2013). Receptor-mediated endocytosis and brain delivery of therapeutic biologics. 2013:703545. doi: 10.1155/2013/703545
   Google Scholar
• Xin H, Sha X, Jiang X, et al. (2012). Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 33:8167–76
   PubMed Web of Science ®Google Scholar
• Zasloff M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci 84:5449–53
   PubMed Web of Science ®Google Scholar
• Zhang P, Hu L, Wang Y, et al. (2010). Poly (ɛ-caprolactone)-block-poly (ethyl ethylene phosphate) micelles for brain-targeting drug delivery: in vitro and in vivo valuation. Pharm Res 27:2657–69
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Morris ME. (2004a). Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208–16
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schuetz JD, Elmquist WF, Miller DW. (2004b). Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 311:449–55
   PubMed Web of Science ®Google Scholar
• Zhao M, Chang J, Fu X, et al. (2012). Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats. J Drug Target 20:416–21
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Wang L-L, Di YM, et al. (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15:1981–2039
   PubMed Web of Science ®Google Scholar